200 related articles for article (PubMed ID: 16418187)
21. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer.
Fossella FV; Lippman SM; Shin DM; Tarassoff P; Calayag-Jung M; Perez-Soler R; Lee JS; Murphy WK; Glisson B; Rivera E; Hong WK
J Clin Oncol; 1997 Jan; 15(1):310-6. PubMed ID: 8996158
[TBL] [Abstract][Full Text] [Related]
22. [Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in treatment of advanced non-small cell lung cancer (NSCLC)].
Zhang L; Zhang Y; Li N; Xu F; Pan ZK; Guan ZZ
Ai Zheng; 2004 Nov; 23(11 Suppl):1455-8. PubMed ID: 15566656
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer.
Xu N; Shen P; Zhang XC; Yu LF; Bao HY; Shi GM; Huang S; Chen J; Mou HB; Fang WJ
Cancer Chemother Pharmacol; 2007 Jan; 59(1):1-7. PubMed ID: 16614849
[TBL] [Abstract][Full Text] [Related]
24. Phase I study of gemcitabine given weekly as a short infusion for non-small cell lung cancer: results and possible immune system-related mechanisms.
Levitt ML; Kassem B; Gooding WE; Miketic LM; Landreneau RJ; Ferson PF; Keenan R; Yousem SA; Lindberg CA; Trenn MR; Ponas RS; Tarasoff P; Sabatine JM; Friberg D; Whiteside TL
Lung Cancer; 2004 Mar; 43(3):335-44. PubMed ID: 15165093
[TBL] [Abstract][Full Text] [Related]
25. Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.
Jang J; Kim HK; Cho BC; Lee KH; Yun HJ; Woo IS; Song HS; Ryoo HM; Kim CH; Sun DS; Shin JW
Cancer Chemother Pharmacol; 2017 May; 79(5):873-880. PubMed ID: 28341958
[TBL] [Abstract][Full Text] [Related]
26. The MILES-2G phase 2 study of single-agent gemcitabine with prolonged constant infusion in advanced non-small cell lung cancer elderly patients.
Gridelli C; De Maio E; Barbera S; Sannicolo M; Piazza E; Piantedosi F; Brancaccio L; Morabito A; Maione P; Renda F; Signoriello G; Perrone F;
Lung Cancer; 2008 Jul; 61(1):67-72. PubMed ID: 18683299
[TBL] [Abstract][Full Text] [Related]
27. A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status.
Cobo M; Gutiérrez V; Alcaide J; Alés I; Villar E; Gil S; Durán G; Martínez J; Carabantes F; Bretón JJ; Benavides M
Lung Cancer; 2007 May; 56(2):255-62. PubMed ID: 17276537
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.
Abratt RP; Bezwoda WR; Falkson G; Goedhals L; Hacking D; Rugg TA
J Clin Oncol; 1994 Aug; 12(8):1535-40. PubMed ID: 8040664
[TBL] [Abstract][Full Text] [Related]
29. Front-line weekly chemotherapy with gemcitabine for unfit patients with non-small cell lung cancer (NSCLC).
Ferrigno D; Buccheri G;
Lung Cancer; 2004 Sep; 45(3):373-80. PubMed ID: 15301878
[TBL] [Abstract][Full Text] [Related]
30. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study.
Perng RP; Chen YM; Ming-Liu J; Tsai CM; Lin WC; Yang KY; Whang-Peng J
J Clin Oncol; 1997 May; 15(5):2097-102. PubMed ID: 9164223
[TBL] [Abstract][Full Text] [Related]
31. Gemcitabine and cisplatin treatment of advanced-stage non-small-cell lung cancer in patients given cisplatin on day 8.
Akcali Z; Calikusu Z; Sakalli H; Ozyilkan O
Tumori; 2008; 94(4):474-80. PubMed ID: 18822681
[TBL] [Abstract][Full Text] [Related]
32. Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the "polmone toscano group" (POLTO).
Tibaldi C; Ricci S; Russo F; Bernardini I; Galli L; Chioni A; Orlandini C; Grosso AM; Pegna AL; Fabbri A; Innocenti F; Ferrari K; Tognarini L; Conte PF; Falcone A;
Lung Cancer; 2005 Apr; 48(1):121-7. PubMed ID: 15777979
[TBL] [Abstract][Full Text] [Related]
33. A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study.
Ng EW; Sandler AB; Robinson L; Einhorn LH
Am J Clin Oncol; 1999 Dec; 22(6):550-3. PubMed ID: 10597737
[TBL] [Abstract][Full Text] [Related]
34. Phase II studies of gemcitabine for non-small cell lung cancer in Japan.
Fukuoka M; Takada M; Yokoyama A; Kurita Y; Niitani H
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-42-S7-46. PubMed ID: 9194479
[TBL] [Abstract][Full Text] [Related]
35. [Late phase II study of LY188011 (gemcitabine hydrochloride) in patient with non-small-cell lung cancer. Gemcitabine Late Phase II Cooperative Study Group A)].
Fukuoka M; Negoro S; Kudo S; Furuse K; Nishikawa H; Takada Y; Kamei T; Niitani H; Taguchi T
Gan To Kagaku Ryoho; 1996 Nov; 23(13):1825-32. PubMed ID: 8937493
[TBL] [Abstract][Full Text] [Related]
36. Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients.
Franciosi V; Barbieri R; Aitini E; Vasini G; Cacciani GC; Capra R; Camisa R; Cascinu S
Lung Cancer; 2003 Jul; 41(1):101-6. PubMed ID: 12826318
[TBL] [Abstract][Full Text] [Related]
37. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
[TBL] [Abstract][Full Text] [Related]
38. [Phase II studies of gemcitabine for non-small cell lung cancer in Japan].
Asai G; Fukuoka M
Gan To Kagaku Ryoho; 1999 Jun; 26(7):884-9. PubMed ID: 10396314
[TBL] [Abstract][Full Text] [Related]
39. A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy.
Cappuzzo F; Novello S; De Marinis F; Selvaggi G; Scagliotti GV; Barbieri F; Maur M; Papi M; Pasquini E; Bartolini S; Marini L; Crinò L
Lung Cancer; 2006 Jun; 52(3):319-25. PubMed ID: 16630670
[TBL] [Abstract][Full Text] [Related]
40. Activity of gemcitabine in non-small-cell lung cancer: results of the Japan gemcitabine group (A) phase II study.
Takada M; Negoro S; Kudo S; Furuse K; Nishikawa H; Takada Y; Kamei T; Niitani H; Fukuoka M
Cancer Chemother Pharmacol; 1998; 41(3):217-22. PubMed ID: 9443638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
